1864 related articles for article (PubMed ID: 33475701)
1. Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial.
Gottlieb RL; Nirula A; Chen P; Boscia J; Heller B; Morris J; Huhn G; Cardona J; Mocherla B; Stosor V; Shawa I; Kumar P; Adams AC; Van Naarden J; Custer KL; Durante M; Oakley G; Schade AE; Holzer TR; Ebert PJ; Higgs RE; Kallewaard NL; Sabo J; Patel DR; Klekotka P; Shen L; Skovronsky DM
JAMA; 2021 Feb; 325(7):632-644. PubMed ID: 33475701
[TBL] [Abstract][Full Text] [Related]
2. Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19.
Dougan M; Nirula A; Azizad M; Mocherla B; Gottlieb RL; Chen P; Hebert C; Perry R; Boscia J; Heller B; Morris J; Crystal C; Igbinadolor A; Huhn G; Cardona J; Shawa I; Kumar P; Adams AC; Van Naarden J; Custer KL; Durante M; Oakley G; Schade AE; Holzer TR; Ebert PJ; Higgs RE; Kallewaard NL; Sabo J; Patel DR; Dabora MC; Klekotka P; Shen L; Skovronsky DM;
N Engl J Med; 2021 Oct; 385(15):1382-1392. PubMed ID: 34260849
[TBL] [Abstract][Full Text] [Related]
3. Effect of Bamlanivimab vs Placebo on Incidence of COVID-19 Among Residents and Staff of Skilled Nursing and Assisted Living Facilities: A Randomized Clinical Trial.
Cohen MS; Nirula A; Mulligan MJ; Novak RM; Marovich M; Yen C; Stemer A; Mayer SM; Wohl D; Brengle B; Montague BT; Frank I; McCulloh RJ; Fichtenbaum CJ; Lipson B; Gabra N; Ramirez JA; Thai C; Chege W; Gomez Lorenzo MM; Sista N; Farrior J; Clement ME; Brown ER; Custer KL; Van Naarden J; Adams AC; Schade AE; Dabora MC; Knorr J; Price KL; Sabo J; Tuttle JL; Klekotka P; Shen L; Skovronsky DM;
JAMA; 2021 Jul; 326(1):46-55. PubMed ID: 34081073
[TBL] [Abstract][Full Text] [Related]
4. SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19.
Chen P; Nirula A; Heller B; Gottlieb RL; Boscia J; Morris J; Huhn G; Cardona J; Mocherla B; Stosor V; Shawa I; Adams AC; Van Naarden J; Custer KL; Shen L; Durante M; Oakley G; Schade AE; Sabo J; Patel DR; Klekotka P; Skovronsky DM;
N Engl J Med; 2021 Jan; 384(3):229-237. PubMed ID: 33113295
[TBL] [Abstract][Full Text] [Related]
5. A Randomized, Placebo-Controlled Clinical Trial of Bamlanivimab and Etesevimab Together in High-Risk Ambulatory Patients With COVID-19 and Validation of the Prognostic Value of Persistently High Viral Load.
Dougan M; Azizad M; Mocherla B; Gottlieb RL; Chen P; Hebert C; Perry R; Boscia J; Heller B; Morris J; Crystal C; Igbinadolor A; Huhn G; Cardona J; Shawa I; Kumar P; Blomkalns A; Adams AC; Van Naarden J; Custer KL; Knorr J; Oakley G; Schade AE; Holzer TR; Ebert PJ; Higgs RE; Sabo J; Patel DR; Dabora MC; Williams M; Klekotka P; Shen L; Skovronsky DM; Nirula A
Clin Infect Dis; 2022 Aug; 75(1):e440-e449. PubMed ID: 34718468
[TBL] [Abstract][Full Text] [Related]
6. Effect of Sotrovimab on Hospitalization or Death Among High-risk Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial.
Gupta A; Gonzalez-Rojas Y; Juarez E; Crespo Casal M; Moya J; Rodrigues Falci D; Sarkis E; Solis J; Zheng H; Scott N; Cathcart AL; Parra S; Sager JE; Austin D; Peppercorn A; Alexander E; Yeh WW; Brinson C; Aldinger M; Shapiro AE;
JAMA; 2022 Apr; 327(13):1236-1246. PubMed ID: 35285853
[TBL] [Abstract][Full Text] [Related]
7. Endogenous Antibody Responses to SARS-CoV-2 in Patients With Mild or Moderate COVID-19 Who Received Bamlanivimab Alone or Bamlanivimab and Etesevimab Together.
Zhang L; Poorbaugh J; Dougan M; Chen P; Gottlieb RL; Huhn G; Beasley S; Daniels M; Ngoc Vy Trinh T; Crisp M; Freitas JJ; Vaillancourt P; Patel DR; Nirula A; Kallewaard NL; Higgs RE; Benschop RJ
Front Immunol; 2021; 12():790469. PubMed ID: 34956222
[TBL] [Abstract][Full Text] [Related]
8. REGEN-COV Antibody Combination and Outcomes in Outpatients with Covid-19.
Weinreich DM; Sivapalasingam S; Norton T; Ali S; Gao H; Bhore R; Xiao J; Hooper AT; Hamilton JD; Musser BJ; Rofail D; Hussein M; Im J; Atmodjo DY; Perry C; Pan C; Mahmood A; Hosain R; Davis JD; Turner KC; Baum A; Kyratsous CA; Kim Y; Cook A; Kampman W; Roque-Guerrero L; Acloque G; Aazami H; Cannon K; Simón-Campos JA; Bocchini JA; Kowal B; DiCioccio AT; Soo Y; Geba GP; Stahl N; Lipsich L; Braunstein N; Herman G; Yancopoulos GD;
N Engl J Med; 2021 Dec; 385(23):e81. PubMed ID: 34587383
[TBL] [Abstract][Full Text] [Related]
9. PK/PD modeling links accelerated resolution of COVID-19-related clinical symptoms to SARS-CoV-2 viral load reduction in patients following treatment with Bamlanivimab alone or Bamlanivimab and Etesevimab together.
Ernest CS; Chien JY; Patel DR; Chigutsa E
CPT Pharmacometrics Syst Pharmacol; 2022 Jun; 11(6):721-730. PubMed ID: 35289125
[TBL] [Abstract][Full Text] [Related]
10. Responses to a Neutralizing Monoclonal Antibody for Hospitalized Patients With COVID-19 According to Baseline Antibody and Antigen Levels : A Randomized Controlled Trial.
; Lundgren JD; Grund B; Barkauskas CE; Holland TL; Gottlieb RL; Sandkovsky U; Brown SM; Knowlton KU; Self WH; Files DC; Jain MK; Benfield T; Bowdish ME; Leshnower BG; Baker JV; Jensen JU; Gardner EM; Ginde AA; Harris ES; Johansen IS; Markowitz N; Matthay MA; Østergaard L; Chang CC; Goodman AL; Chang W; Dewar RL; Gerry NP; Higgs ES; Highbarger H; Murray DD; Murray TA; Natarajan V; Paredes R; Parmar MKB; Phillips AN; Reilly C; Rupert AW; Sharma S; Shaw-Saliba K; Sherman BT; Teitelbaum M; Wentworth D; Cao H; Klekotka P; Babiker AG; Davey VJ; Gelijns AC; Kan VL; Polizzotto MN; Thompson BT; Lane HC; Neaton JD
Ann Intern Med; 2022 Feb; 175(2):234-243. PubMed ID: 34928698
[TBL] [Abstract][Full Text] [Related]
11. Population Pharmacokinetics and Pharmacodynamics of the Neutralizing Antibodies Bamlanivimab and Etesevimab in Patients With Mild to Moderate COVID-19 Infection.
Chigutsa E; O'Brien L; Ferguson-Sells L; Long A; Chien J
Clin Pharmacol Ther; 2021 Nov; 110(5):1302-1310. PubMed ID: 34514598
[TBL] [Abstract][Full Text] [Related]
12. Effect of Subcutaneous Casirivimab and Imdevimab Antibody Combination vs Placebo on Development of Symptomatic COVID-19 in Early Asymptomatic SARS-CoV-2 Infection: A Randomized Clinical Trial.
O'Brien MP; Forleo-Neto E; Sarkar N; Isa F; Hou P; Chan KC; Musser BJ; Bar KJ; Barnabas RV; Barouch DH; Cohen MS; Hurt CB; Burwen DR; Marovich MA; Brown ER; Heirman I; Davis JD; Turner KC; Ramesh D; Mahmood A; Hooper AT; Hamilton JD; Kim Y; Purcell LA; Baum A; Kyratsous CA; Krainson J; Perez-Perez R; Mohseni R; Kowal B; DiCioccio AT; Geba GP; Stahl N; Lipsich L; Braunstein N; Herman G; Yancopoulos GD; Weinreich DM;
JAMA; 2022 Feb; 327(5):432-441. PubMed ID: 35029629
[TBL] [Abstract][Full Text] [Related]
13. REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19.
Weinreich DM; Sivapalasingam S; Norton T; Ali S; Gao H; Bhore R; Musser BJ; Soo Y; Rofail D; Im J; Perry C; Pan C; Hosain R; Mahmood A; Davis JD; Turner KC; Hooper AT; Hamilton JD; Baum A; Kyratsous CA; Kim Y; Cook A; Kampman W; Kohli A; Sachdeva Y; Graber X; Kowal B; DiCioccio T; Stahl N; Lipsich L; Braunstein N; Herman G; Yancopoulos GD;
N Engl J Med; 2021 Jan; 384(3):238-251. PubMed ID: 33332778
[TBL] [Abstract][Full Text] [Related]
14. Effect of Bamlanivimab as Monotherapy or in Combination with Etesevimab or Sotrovimab on Persistently High Viral Load in Patients with Mild-to-Moderate COVID-19: A Randomized, Phase 2 BLAZE-4 Trial.
Nichols RM; Macpherson L; Patel DR; Yeh WW; Peppercorn A
Infect Dis Ther; 2024 Feb; 13(2):401-411. PubMed ID: 38291279
[TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of inhaled IBIO123 for mild-to-moderate COVID-19: a randomised, double-blind, dose-ascending, placebo-controlled, phase 1/2 trial.
Maranda B; Labbé SM; Lurquin M; Brabant P; Fugère A; Larrivée JF; Grbic D; Leroux A; Leduc F; Finzi A; Gaudreau S; Swart Y;
Lancet Infect Dis; 2024 Jan; 24(1):25-35. PubMed ID: 37619584
[TBL] [Abstract][Full Text] [Related]
16. Bamlanivimab plus etesevimab treatment have a better outcome against COVID-19: A meta-analysis.
Xiang HR; He B; Li Y; Cheng X; Zhang QZ; Peng WX
J Med Virol; 2022 May; 94(5):1893-1905. PubMed ID: 34936121
[TBL] [Abstract][Full Text] [Related]
17. Do we need bamlanivimab? Is etesevimab a key to treating Covid-19?
Doggrell SA
Expert Opin Biol Ther; 2021 Nov; 21(11):1359-1362. PubMed ID: 34555986
[TBL] [Abstract][Full Text] [Related]
18. Bamlanivimab and Etesevimab Improve Symptoms and Associated Outcomes in Ambulatory Patients at Increased Risk for Severe Coronavirus Disease 2019: Results From the Placebo-Controlled Double-Blind Phase 3 BLAZE-1 Trial.
Chen P; Behre G; Hebert C; Kumar P; Farmer Macpherson L; Graham-Clarke PL; De La Torre I; Nichols RM; Hufford MM; Patel DR; Naegeli AN
Open Forum Infect Dis; 2022 May; 9(5):ofac172. PubMed ID: 35493124
[TBL] [Abstract][Full Text] [Related]
19. Peginterferon lambda for the treatment of outpatients with COVID-19: a phase 2, placebo-controlled randomised trial.
Feld JJ; Kandel C; Biondi MJ; Kozak RA; Zahoor MA; Lemieux C; Borgia SM; Boggild AK; Powis J; McCready J; Tan DHS; Chan T; Coburn B; Kumar D; Humar A; Chan A; O'Neil B; Noureldin S; Booth J; Hong R; Smookler D; Aleyadeh W; Patel A; Barber B; Casey J; Hiebert R; Mistry H; Choong I; Hislop C; Santer DM; Lorne Tyrrell D; Glenn JS; Gehring AJ; Janssen HLA; Hansen BE
Lancet Respir Med; 2021 May; 9(5):498-510. PubMed ID: 33556319
[TBL] [Abstract][Full Text] [Related]
20. Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.
Dioh W; Chabane M; Tourette C; Azbekyan A; Morelot-Panzini C; Hajjar LA; Lins M; Nair GB; Whitehouse T; Mariani J; Latil M; Camelo S; Lafont R; Dilda PJ; Veillet S; Agus S
Trials; 2021 Jan; 22(1):42. PubMed ID: 33430924
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
